Key result
Growth hormone has emerged as a candidate for increasing cardiac performance and possibly survival in patients with idiopathic dilated cardiomyopathy.
Why the study?
Does growth hormone improve cardiac performance and survival in patients with idiopathic dilated cardiomyopathy?
Does growth hormone improve cardiac performance and survival in patients with idiopathic dilated cardiomyopathy?
Growth hormone is being explored as a potential candidate to increase cardiac performance and survival in patients with end-stage dilated cardiomyopathy.
Hypothesis-generating for growth hormone in idiopathic dilated cardiomyopathy; leaves open effects on performance and survival.
Idiopathic dilated cardiomyopathy is a common cause of heart failure. Despite advances in treatment, this disease has a mean survival time of 5 years (1). Currently, the only effective treatment for end-stage dilated cardio-myopathy is heart transplantation. However, additional, more conservative treatment options are being explored to prolong survival until an organ becomes available or even to obviate the necessity for transplantation. Left ventricular assist devices or partial left ventriculectomy, infusions of catecholamine analogs, and phosphodies-terase inhibitors are among some of the treatment options which are being experimentally evaluated (1 and references therein). In addition to these, growth hormone (GH) has emerged as a candidate for increas-ing cardiac performance, and thus possibly survival, in
No takes yet. Share an insight, caveat, or question.
Mohammad Arafat Hussain (1998) conducted an editorial in Idiopathic dilated cardiomyopathy. Growth hormone was evaluated. Growth hormone has emerged as a candidate for increasing cardiac performance and possibly survival in patients with idiopathic dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: